Jun 15, 2022 / 01:30PM GMT
Douglas Royal Buchanan - JMP Securities LLC, Research Division - Director & Equity Research Analyst
Thank you. Thanks, everyone, for joining us for the JMP Securities Life Sciences Conference. My name is Roy Buchanan, a biotech analyst. We have with us today, Pierre Kemula, Chief Financial Officer of CureVac, tell us a bit about CureVac.
Questions and Answers:
Douglas Royal Buchanan - JMP Securities LLC, Research Division - Director & Equity Research AnalystSo I'm actually going to start since we have the CFO up here, start on cash. I think we had about 2 years of cash in our model. Can you just describe where you are in cash, how far it gets you? There's a little bit more cost for this CVnCoV wind-down than we expected in 1Q. What's the outlook for that going forward? Is there more remaining?
Pierre Kemula - CureVac N.V. - MD, CFO & Member of Management Board
Great. Well, thank you, Roy. Good morning to everyone. It's a pleasure to be here. So happy to take the question, of course. So we ended Q1
Trustpilot
